Reading the annual reports…

First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.

Medicenna Therapeutics Corp. (MDNAF) financial health, profit and balance sheet · Scorvest

MDNAF · OTC · United States · Pharmaceutical Preparations

Medicenna Therapeutics Corp.

Toronto · Fiscal year ends in March · Figures in CAD

In shortMedicenna Therapeutics Corp. is loss-making.

Financial health

Weak

Built from five areas over the last five annual reports. Tap an area to see the figures behind it.

Profitability0

Operating marginShare of each sale left after running the business, before interest and tax.	–	n/a
Net marginShare of each sale left as profit after every cost, interest and tax.	–	n/a
Return on equityProfit earned on the money shareholders put in. Above 15% is strong.	-39.9%	0/100
Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge.	–	n/a

Weight in the score: 25%

Balance sheet100

Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash.	9.57×	100/100
Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted.	–	n/a
Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable.	–	n/a
Interest coverageHow many times operating profit covers interest. Below 2 is risky.	–	n/a
Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress.	–	n/a

Weight in the score: 25%

Cash generation0

Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt.	–	n/a
Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy.	–	n/a
Years with positive free cash flow (last 5)	0 of 3	0/100

Weight in the score: 20%

Stability0
Profitable years (last 5) 0 of 4 0/100
Years of revenue decline (last 5) – n/a
Revenue growth volatility – n/a
Operating margin volatility – n/a
Weight in the score: 20%
Growth–
Revenue growth, 3-year average – n/a
EPS growth, 3-year average – n/a
Weight in the score: 10%

Profitable years (last 5)	0 of 4	0/100
Years of revenue decline (last 5)	–	n/a
Revenue growth volatility	–	n/a
Operating margin volatility	–	n/a

Revenue growth, 3-year average	–	n/a
EPS growth, 3-year average	–	n/a

Fiscal year 2023 · change vs prior year

Annual figures as reported. Hover a bar or point for the exact value.

RevenueNet income

No data reported.

The last 4 fiscal years from the company's annual reports.

CAD millions; negative values in parentheses.

Fiscal year	FY20	FY21	FY22	FY23
Research & development	5.9	11	15	9.3
Pre-tax income	(8.3)	(17)	(23)	(10)
Income tax	0	0	0	0
Net income	(8.3)	(17)	(23)	(10)
Diluted EPS	−C$0.26	−C$0.35	–	–
Diluted shares (millions)	32	50	54	65

Not computed: a required balance-sheet item is missing.

Not computed: it needs two consecutive complete years.

All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works

Latest annual report: Mar 31, 2023 · Data updated Jun 27, 2023